Tran Phuoc T, Su Zheng, Lee Percy, Lavori Philip, Husain Amreen, Teng Nelson, Kapp Daniel S
Department of Radiation Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.
Gynecol Oncol. 2007 Jun;105(3):641-9. doi: 10.1016/j.ygyno.2007.01.033. Epub 2007 Mar 23.
To analyze the results of treatment and identify prognostic factors for primary squamous cell carcinoma (SCCA) of the vagina managed with radiotherapy at a single institution.
Seventy-eight patients were analyzed in this retrospective series. Mean characteristics: follow-up 89 months; age 65 years (range 33-99); tumor size 3.8 cm (0.3-10); treatment hemoglobin 12.4 g/dl (range 8.7-14.4); and tumor dose 72 Gy (range 6-127). In addition, 49% of our cohort had a prior hysterectomy. The FIGO stage distribution: I (42%); II (29%); III (17%); and IVA/B (11%). Sixty-two percent of patients were treated with a combination of external beam radiation (EBRT) and brachytherapy, 22% with EBRT alone and 13% with brachytherapy alone.
Kaplan-Meier (KM) 5-year pelvic control, distant metastasis free survival and disease specific survival probabilities: stage I, 83%, 100%, and 92%; stage II, 76%, 95%, and 68%; stage III, 62%, 65%, and 44%; and stage IV, 30%, 18%, and 13%. On multivariate analysis: stage; treatment hemoglobin; and prior hysterectomy were prognostic for DSS (p<0.05). The KM 5-year grade 3/4 (G3/4) complication free estimate of our cohort was 84%. G3/4 complications: tumor size and tumor dose were independently predictive (p<0.05).
Radiotherapy as a single modality for early stage primary vaginal SCCA produces good results. Advanced stage disease necessitates a combined modality approach and/or new methods. Treatment Hg levels appear to be clinically significant and studies on correction of anemia during treatment are warranted.
分析在单一机构接受放射治疗的原发性阴道鳞状细胞癌(SCCA)的治疗结果并确定预后因素。
对本回顾性系列中的78例患者进行分析。平均特征:随访89个月;年龄65岁(范围33 - 99岁);肿瘤大小3.8 cm(0.3 - 10 cm);治疗时血红蛋白12.4 g/dl(范围8.7 - 14.4 g/dl);肿瘤剂量72 Gy(范围6 - 127 Gy)。此外,我们队列中的49%患者曾接受过子宫切除术。国际妇产科联盟(FIGO)分期分布:I期(42%);II期(29%);III期(17%);IVA/B期(11%)。62%的患者接受了外照射放疗(EBRT)和近距离放疗联合治疗,22%仅接受EBRT治疗,13%仅接受近距离放疗治疗。
Kaplan - Meier(KM)5年盆腔控制率、无远处转移生存率和疾病特异性生存率:I期分别为83%、100%和92%;II期分别为76%、95%和68%;III期分别为62%、65%和44%;IV期分别为30%、18%和13%。多因素分析显示:分期、治疗时血红蛋白水平和既往子宫切除术对疾病特异性生存(DSS)具有预后意义(p<0.05)。我们队列的KM 5年3/4级(G3/4)无并发症估计率为84%。G3/4级并发症:肿瘤大小和肿瘤剂量具有独立预测性(p<0.05)。
放疗作为早期原发性阴道SCCA的单一治疗方式可产生良好效果。晚期疾病需要联合治疗方式和/或新方法。治疗时血红蛋白水平似乎具有临床意义,有必要开展关于治疗期间纠正贫血的研究。